Ear gel may shield cancer patients from Chemo-Induced deafness

NCT ID NCT07281508

Recruiting now Prevention Sponsor: The Netherlands Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether injecting a special gel (sodium thiosulfate) into the ear before each round of cisplatin chemotherapy can prevent hearing loss. About 100 adults with head and neck cancer will receive the gel in one ear only, so the treated ear can be compared to the untreated ear. The goal is to see if the gel protects hearing without affecting the cancer treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CISPLATIN-RELATED HEARING LOSS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer platinum-induced ototoxicity prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CISPLATIN-RELATED HEARING LOSS

Contacts and locations

Locations

Antoni van Leeuwenhoek
RECRUITING

Amsterdam, North Holland, 1066CX, Netherlands
Erasmus Universitair Medisch Centrum Rotterdam
NOT_YET_RECRUITING

Rotterdam, South Holland, 3015GD, Netherlands
Leiden University Medical Center
RECRUITING

Leiden, South Holland, 2333ZA, Netherlands
Stichting Radboud University Medical Center
NOT_YET_RECRUITING

Nijmegen, 6525GA, Netherlands
University Medical Center Utrecht
NOT_YET_RECRUITING

Utrecht, Utrecht, 3584CX, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.